Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Current Investments: 2013-2024

Historic Cash & Current Investments for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $57.3 million.

  • Fortress Biotech's Cash & Current Investments rose 46.50% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.2 million, marking a year-over-year increase of 3.15%. This contributed to the annual value of $57.3 million for FY2024, which is 29.24% down from last year.
  • According to the latest figures from FY2024, Fortress Biotech's Cash & Current Investments is $57.3 million, which was down 29.24% from $80.9 million recorded in FY2023.
  • Fortress Biotech's 5-year Cash & Current Investments high stood at $310.2 million for FY2020, and its period low was $57.3 million during FY2024.
  • In the last 3 years, Fortress Biotech's Cash & Current Investments had a median value of $80.9 million in 2023 and averaged $105.5 million.
  • Per our database at Business Quant, Fortress Biotech's Cash & Current Investments skyrocketed by 104.24% in 2020 and then crashed by 54.60% in 2023.
  • Yearly analysis of 5 years shows Fortress Biotech's Cash & Current Investments stood at $310.2 million in 2020, then declined by 1.42% to $305.7 million in 2021, then crashed by 41.69% to $178.3 million in 2022, then tumbled by 54.60% to $80.9 million in 2023, then decreased by 29.24% to $57.3 million in 2024.